CA2015687A1 - Human serum albomin fusion polypeptide - Google Patents

Human serum albomin fusion polypeptide

Info

Publication number
CA2015687A1
CA2015687A1 CA2015687A CA2015687A CA2015687A1 CA 2015687 A1 CA2015687 A1 CA 2015687A1 CA 2015687 A CA2015687 A CA 2015687A CA 2015687 A CA2015687 A CA 2015687A CA 2015687 A1 CA2015687 A1 CA 2015687A1
Authority
CA
Canada
Prior art keywords
terminal
terminal portion
human serum
fusion polypeptide
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2015687A
Other languages
French (fr)
Other versions
CA2015687C (en
Inventor
David J. Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2015687A1 publication Critical patent/CA2015687A1/en
Application granted granted Critical
Publication of CA2015687C publication Critical patent/CA2015687C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of human serum albumin (HSA) or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is one of various specified entities, including the 585 to 1578 portion of human fibronectin or a variant thereof. The HSA-like portion may have additional N-terminal residues, such as secretion leader sequences (signal sequences). The C-terminal portion is preferably the 585-1578 portion of human plasma fibronectin.
The N-terminal and C-terminal portions may be cleavable to yield the isolated C-terminal portion, with the N-terminal portion having served to facilitate secretion from the host.
CA002015687A 1989-04-29 1990-04-27 Human serum albomin fusion polypeptide Expired - Lifetime CA2015687C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898909916A GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides
GBGB8909916.2 1989-04-29

Publications (2)

Publication Number Publication Date
CA2015687A1 true CA2015687A1 (en) 1990-10-29
CA2015687C CA2015687C (en) 2000-08-29

Family

ID=10656000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002015687A Expired - Lifetime CA2015687C (en) 1989-04-29 1990-04-27 Human serum albomin fusion polypeptide

Country Status (12)

Country Link
EP (1) EP0470165A1 (en)
JP (1) JP2781459B2 (en)
KR (1) KR100227167B1 (en)
AU (1) AU630450B2 (en)
CA (1) CA2015687C (en)
FI (1) FI104255B1 (en)
GB (2) GB8909916D0 (en)
HU (1) HUT61049A (en)
IE (1) IE67651B1 (en)
IL (1) IL94243A (en)
WO (1) WO1990013653A1 (en)
ZA (1) ZA903237B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
GB9408466D0 (en) * 1994-04-27 1994-06-22 Univ Nottingham Cloning and functional expression of neurotoxins
US5543308A (en) * 1994-10-18 1996-08-06 New England Biolabs, Inc. Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
MY120425A (en) * 1996-07-26 2005-10-31 Novartis Ag Fusion polypeptides
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
US5932693A (en) * 1996-12-10 1999-08-03 Washington University Antithrombotic peptides
EP1049790A1 (en) 1998-01-23 2000-11-08 Novo Nordisk A/S Process for making desired polypeptides in yeast
WO1999066054A2 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Erythropoietin analog-human serum albumin fusion protein
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003016511A1 (en) 2001-08-15 2003-02-27 Takara Bio Inc. Method of extended culture for antigen-specific cytotoxic t lumphocytes
ES2500918T3 (en) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
KR100895231B1 (en) 2002-03-25 2009-05-04 다카라 바이오 가부시키가이샤 Process for producing cytotoxic lymphocyte
EP1666589B1 (en) 2003-08-22 2010-02-17 Takara Bio Inc. Process for producing cytotoxic lymphocytes
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
US9139611B2 (en) 2006-07-13 2015-09-22 Novozymes Biopharma Dk A/S Process for preparing particles of proteinaceous material
EP3243835B1 (en) 2009-02-11 2024-04-10 Albumedix Ltd Albumin variants and conjugates
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
EP2723370A4 (en) * 2011-06-24 2015-06-03 Univ Colorado Regents Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
BR112018003179A2 (en) 2015-08-20 2018-09-25 Albumedix As albumin conjugates and variants
EP3538560A4 (en) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
BR112021008200A2 (en) * 2018-10-29 2021-12-14 Spin Therapeutics Llc Compositions and methods for alpha-1-antitrypsin disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE459586B (en) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides

Also Published As

Publication number Publication date
GB8909916D0 (en) 1989-06-14
GB2246783B (en) 1992-10-14
IE901554L (en) 1990-10-29
ZA903237B (en) 1991-03-27
FI104255B (en) 1999-12-15
AU5564690A (en) 1990-11-29
GB9119043D0 (en) 1991-12-04
IE67651B1 (en) 1996-04-17
FI104255B1 (en) 1999-12-15
GB2246783A (en) 1992-02-12
WO1990013653A1 (en) 1990-11-15
EP0470165A1 (en) 1992-02-12
CA2015687C (en) 2000-08-29
AU630450B2 (en) 1992-10-29
HU904413D0 (en) 1992-01-28
KR920701451A (en) 1992-08-11
KR100227167B1 (en) 1999-10-15
IL94243A0 (en) 1991-01-31
JP2781459B2 (en) 1998-07-30
HUT61049A (en) 1992-11-30
IL94243A (en) 1995-10-31
JPH04506598A (en) 1992-11-19
FI915073A0 (en) 1991-10-28

Similar Documents

Publication Publication Date Title
CA2015687A1 (en) Human serum albomin fusion polypeptide
CA2050336A1 (en) Yeast processing system comprising a negatively charged amino acid adjacent to the processing site
AU9156291A (en) Polypeptide analogs of apolipoprotein e, diagnostic systems and methods using the analogs
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
AU543198B2 (en) Hexapeptides
EP0370989A3 (en) Human vascular permeability factor
IL70601A (en) Synthetic heat-stable enterotoxin polypeptides of escherichia coli,multimers thereof,vaccines,diagnostic systems and network polymers including same and methods for their preparation
EP0330451A3 (en) A cdna coding for human normal serum albumin a, and a process for production of the albumin
AU4647889A (en) Insect signal peptide mediated secretion of recombinant proteins
AU3498189A (en) Fibronectin binding protein
KR100295606B1 (en)
EP0187721A3 (en) Preparation of peptide substrates for virus-specified proteases
WO2001025438A3 (en) Ifn-alpha homologues
EP0249477A3 (en) Functional recombinant analog polypeptides devoid of hydrophobic amino acids
Gluschankof et al. The somatostatin-28 convertase of rat brain cortex generates both somatostatin-14 and somatostatin-28 (1–12)
AU8680691A (en) Intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
CA2133834A1 (en) Process for preparing modified proteins
WO1988006625A3 (en) Arginine-depleted human tumor necrosis factor
AU7166891A (en) Method of purifying recombinant polypeptides
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
AU2117388A (en) Recombinant htlv-iii proteins and uses thereof
AU4076189A (en) Recombinant fusion proteins for altering hormone secretion
AU637589B2 (en) Ancrod proteins, their production and use
AU2946800A (en) (hansenula polymorpha) mutants and process for the preparation of recombinant proteins using the same
EP0290029A3 (en) (19-alanine) calcitonin

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry